Clostridium Novyi-Nt
Malignant Neoplasms of Lip Oral Cavity and Pharynx
M.D. Anderson Cancer CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
141 Active assets in the Malignant Neoplasms of Lip Oral Cavity and Pharynx cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Instituto Nacional de Cancer, Brazil | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II ImmunityBio, Inc. | Phase 3 | BB |
LIDOCAINE Instituto Nacional de Cancer, Brazil | Phase 3 | BB |
Carboplatin Rapa Therapeutics LLC | Phase 3 | BB |
Cyclophosphamide Zelluna Immunotherapy AS | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Clostridium Novyi-Nt is also rated in:
Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous SystemDormant
CC
Indicative ·
43 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →